CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$5.40 USD
+0.18 (3.38%)
Updated Apr 23, 2024 02:48 PM ET
After-Market: $5.28 -0.12 (-2.22%) 5:08 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
CollPlant Biotechnologies Ltd. Sponsored ADR [CLGN]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: Reports 3rd Quarter Results- $29M cash Runway
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CLGN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Collaboration Milestone Achieved; Pipeline Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: Reports 2nd Quarter Results- Picks Up $10M from AbbVie
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: AbbVie Pays CollPlant $10M - Milestone Realized
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
New 3D Printing Partnership; Anticipated 2023 Milestone Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: We Have Reworked the Model - No Change to Our Target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Focus on Milestone Payments; Lower PT To $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: CollPlant Issues Letter to Shareholders
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: CollPlant: Proof of Concept in 3D Bioprinted Regenerative Breast Implants in Porcine Study
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: Reports the Quarter: $33M in Cash Plus Pipeline Progress
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: Reports the Quarter: $33M in Cash Plus Pipeline Progress
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: CollPlant Expands rhCollagen-Based Bioink Platform
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: CollPlant Reports 2nd Quarter 2022 Results
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: CollPlant Biotechnologies Ltd. Sponsored ADR
Industry: Medical - Drugs
BUY: CollPlant Reports 2021 Results Lowering our PT: $20 to $17
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J